After years of increases, the U.S. adult obesity rate is falling. According to a recent Gallup survey, part of its National Health & Well-Being Index, the rate dropped from about 39.9% in 2022 to 37.0% in 2025, which translates to roughly 7.6 million fewer adults classified as obese. Diabetes is not following. Diagnosis rates continue to climb, to about 13.8%, despite falling obesity rates.
Obesity breaks its upward trend
The decline comes after a long climb. The national adult obesity rate rose from 25.5% in 2008 to nearly 40% by 2022. Compared with the early 1960s, when it was just around 13%, prevalence has tripled.
The turn has come with the spread of GLP-1 (glucagon-like peptide-1) drugs such as Ozempic and Wegovy, which are mainly used for weight loss and for insulin control after meals. Self-reported use of GLP-1 weight-loss drugs (semaglutide and tirzepatide, under brands like Ozempic, Wegovy and Zepbound) rose from about 5.8% in early 2024 to about 12.4% in 2025.
Plotted together for 2018 to 2025, Gallup’s data show obesity rising for years, peaking near 40% in 2022, then falling to 37% as more than 12% of adults began using GLP-1 medications. The biggest obesity drops occurred among 40 to 49 and 50 to 64 year olds (declines of about 4.3 and 5.0 percentage points), the groups that also had the highest uptake of these medications.
The drop in points may not seem significant. But breaking the upward trend in obesity is a major public health and economic breakthrough.
Why diabetes is still rising
Gallup’s figures show the diabetes rate moving the other way, from 11.4% in 2017 to 13.6% in 2023 and 13.8% in 2025. There are a few possible reasons:
- Chronic condition: once diagnosed, patients stay in prevalence data for life.
- Better screening: more early pre-diabetic testing means more reported cases.
- Access gap: GLP-1 drugs are costly and not fully covered by insurance.
- Inequality: wealthier groups see obesity drops, while lower-income groups still face higher diabetes risk.
Reading the numbers with care
This is a positive update on the U.S. obesity rate, but Gallup’s figures use self-reported height and weight, which tends to underreport BMI and mischaracterize weight loss. Higher-quality, long-term data is needed.
If the trend continues, a potential $170B health-cost reversal may be underway. Obesity is associated with substantial direct medical costs, about $170 billion or more annually in the U.S.
Several questions follow. How will the pill form of GLP-1 affect this trend? Can the progress be sustained and made equitable, or will cost and access barriers slow the momentum? And how durable is the weight loss from GLP-1s after people stop taking them?
That last question is the one to keep following. Studies show that when patients stop, they regain about two-thirds of their lost weight within one year. Any interruption in supply, whether from manufacturing delays, insurance pauses or shortages, could mean a population-wide weight rebound within 6 to 18 months.